Biogen Inc. stock reaches a new 52-week high
AD HOC NEWS
Biogen Inc. (BIIB) stock closed at a new 52-week high of USD 224.87 on September 22, 2026, driven by strong Q2 2026 earnings and positive analyst revisions, particularly concerning its lupus drug litifilimab. The company reported adjusted EPS of USD 3.60, significantly beating expectations, and revenue of USD 2.74 billion. Pipeline developments and future clinical readouts are expected to be key factors in sustaining the stock's performance.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.